K Wah Group’s subsidiary has taken part in the tumour therapy and drug developer’s $29.3m round, which came a year after its $28m series B round.
China-based immunotherapy developer Hrain Biotechnology has raised RMB200m ($29.3m) in a series B-plus round featuring conglomerate K Wah Group’s investment subsidiary, Qianhai Wanhui Equity Investment Management.
The round included Guangdong Chongye Holdings, Hengzhen Investment, Junchenda Capital, NSR Financial, Shanghai Pudong Innovation Technology Group, Sino-Singapore Connectivity Private Equity Fund Management and Xinyi Capital.
Founded in 2015, Hrain is developing oncology treatments and drugs. It conducts research and development surrounding chimeric antigen receptor T-cell (CAR-T) technology, which artificially generates T-cell receptors, which…
